TGaS Advisors Teams with UK’s Mirador Analytics to Bring a New Level of Forecasting to today’s Complex Biopharmaceutical Environment
From TGaS Advisors' Press Room
E. Norriton, Penn. and Melrose, UK. 9.14.17. Credible forecasts create hundreds of millions of dollars of additional value for biopharma companies and investors, according to research by TGaS Advisors, a benchmarking and advisory services firm for life sciences commercial operations. Understanding asset evaluation is considered a critical element of the drug commercialization process and a fundamental component underpinning global commercial strategy development. To enable life sciences companies to maximize both their asset development and strategic launch plans, TGaS has formed a partnership with Mirador Analytics, Ltd., a UK company with advanced global forecasting capabilities. The partnership makes asset forecasting and benchmarking available as a holistic service offering to global biopharmaceutical organizations.
